Clinical development of type 1 diabetes vaccine

LU Shiping; JIN Liang; WU Jie

doi:10.11665/j.issn.1000-5048.20140603

Journal of China Pharmaceutical University > 2014 > 45(6): 625-632. > DOI: 10.11665/j.issn.1000-5048.20140603

LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603

Citation:

LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603

Citation:

LU Shiping, JIN Liang, WU Jie. Clinical development of type 1 diabetes vaccine[J]. Journal of China Pharmaceutical University, 2014, 45(6): 625-632. DOI: 10.11665/j.issn.1000-5048.20140603

PDF (5433 KB)

Clinical development of type 1 diabetes vaccine

More Information

Graphical Abstract

Abstract

Abstract

Type 1 diabetes is an autoimmune disorder due to the pancreatic β cell damage with pancreatic inflammation and insulin resistance. For a long time, patients must inject insulin for treatment. Along with advanced development about type 1 diabetes, prevention and early diagnosis of diabetes become possible. This review summarizes the clinical and preclinical stagesintype 1 diabetes vaccine research as well as the recent researches about major biological targets, such as autoantigens or relevant monoclonal antibody and cytokines, respectively.
- type 1 diabetes,
- vaccine,
- autoantigen,
- monoclonal antibody,
- clinical development

FullText(HTML)

References (55)

References

[1]	Kilpatrick ES,Rigby AS,Atkin SL.Insulin resistance,the metabolic syndrome,and complication risk in type 1 diabetes “double diabetes” in the diabetes control an pancreatic islet autoantibodies as predictors of type 1d complications trial[J].Diabetes Care,2007,30(3):707-712.
[2]	Thorn LM,Forsblom C,Fagerudd J,et al.Metabolic syndrome in type 1 diabetes association with diabetic nephropathy and glycemic control(the FinnDiane study)[J].Diabetes Care,2005,28(8):2 019-2 024.
[3]	Gill GV,Woodward A,Casson IF,et al.Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes-the ‘dead in bed’ syndrome revisited[J].Diabetologia,2009,52(1):42-45.
[4]	Pipeleers D,Ling Z.Pancreatic beta cells in insulin-dependent diabetes[J].Diabetes Metab Res Rev,1992,8(3):209-227.
[5]	Diabetes Prevention Trial-Type 1 Diabetes Study Group.Effects of insulin in relatives of patients with type 1 diabetes mellitus[J].N Engl J Med,2002,346(22):1 685-1 691.
[6]	Staeva-Vieira T,Peakman M,Von Herrath M.Translational mini-review series on type 1 diabetes:immune-based therapeutic approaches for type 1 diabetes[J].Clin Exp Immunol,2007,148(1):17-31.
[7]	Lernmark Å, Larsson HE. Immune therapy in type 1 diabetes mellitus[J].Nat Rev Endocrinol,2013,9(2):92-103.
[8]	Jensen RA,Gilliam LK,Törn C,et al.Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15-to 35-year-old diabetic subjects[J].J Diabetes Complications,2007,21(4):205-213.
[9]	Orban T, Sosenko JM, Cuthbertson D, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the diabetes prevention trial- type 1[J].Diabetes Care,2009,32(12):2 269-2 274.
[10]	Barker JM,Barriga KJ,Yu L,et al.Prediction of autoantibody positivity and progression to type 1 diabetes:diabetes autoimmunity study in the young(DAISY)[J].J Clin Endocrinol Metab,2004,89(8):3 896-3 902.
[11]	Wenzlau JM,Juhl K,Yu L,et al.The cation efflux transporter ZnT8(Slc30A8)is a major autoantigen in human type 1 diabetes[J].Proc Natl Acad Sci U S A,2007,104(43):17 040-17 045.
[12]	Harrison LC.Vaccination against self to prevent autoimmune disease:the type 1 diabetes model[J].Immunol Cell Biol,2008,86(2):139-145.
[13]	Clemente-Casares X,Tsai S,Huang C,et al.Antigen-specific therapeutic approaches in type 1 diabetes[J].Cold Spring Harb Perspect Med,2012,2(2):a007773.
[14]	Davidson MB.Insulin analogs—is there a compelling case to use them?No[J]!Diabetes Care,2014,37(6):1 771-1 774.
[15]	Fourlanos S,Perry C,Gellert SA,et al.Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes[J].Diabetes,2011,60(4):1 237-1 245.
[16]	http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403122.htm.
[17]	Orban T,Farkas K,Jalahej H,et al.Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy[J].J Autoimmun,2010,34(4):408-415.
[18]	Garg SK,Buse JB,Skyler JS,et al.Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes[J].Diabetes Obes Metab,2014,16(11):1 065-1 069.
[19]	Ludvigsson J,Krisky D,Casas R,et al.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus[J].N Engl J Med,2012,366(5):433-442.
[20]	Raz I,Elias D,Avron A,et al.β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide(DiaPep277):a randomised,double-blind,phase II trial[J].Lancet,2001,358(9 295):1 749-1 753.
[21]	Schloot NC,Meierhoff G,Lengyel C,et al.Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1:two prospective,randomized,double-blind phase II trials[J].Diabetes Metab Res Rev,2007,23(4):276-285.
[22]	Fischer B,Elias D,Bretzel RG,et al.Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes-an update[J].Expert Opin Biol Ther,2010,10(2):265-272.
[23]	Raz I,Ziegler A G,Linn T,et al.Treatment of recent-onset type 1 diabetic patients with DiaPep277:results of a double-blind,placebo-controlled,randomized phase 3 trial[J].Diabetes Care,2014,37(5):1 392-1 400.
[24]	Liang J,Aihua Z,Yu W,et al.HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration[J].Vaccine,2010,28(19):3 312-3 317.
[25]	Hinman RM,Smith MJ,Cambier JC.B cells and type 1 diabetes…in mice and men[J].Immunol Lett,2014.
[26]	Herold KC,Pescovitz MD,McGee P,et al.Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody(rituximab)therapy in type 1 diabetes[J].J Immunol,2011,187(4):1 998-2 005.
[27]	Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function:two-year results[J].Diabetes Care,2014,37(2):453-459.
[28]	Hu C,Ding H,Zhang X,et al.Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes[J].Diabetes,2013,62(8):2 849-2 858.
[29]	Sarikonda G,Sachithanantham S,Manenkova Y,et al.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin:immunologic effects and efficacy in NOD mice[J].PLoS One,2013,8(2):e54712.
[30]	Herold KC,Pescovitz MD,McGee P,et al.Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody(rituximab)therapy in type 1 diabetes[J].J Immunol,2011,187(4):1 998-2 005.
[31]	Penaranda C,Tang Q,Bluestone JA.Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells[J].J Immunol,2011,187(4):2 015-2 022.
[32]	Hagopian W,Ferry RJ,Sherry N,et al.Teplizumab preserves C-peptide in recent-onset type 1 diabetes two-year results from the randomized,placebo-controlled Protégé trial[J].Diabetes,2013,62(11):3 901-3 908.
[33]	Daifotis AG,Koenig S,Chatenoud L,et al.Anti-CD3 clinical trials in type 1 diabetes mellitus[J].Clin Immunol,2013,149(3):268-278.
[34]	Keymeulen B,Walter M,Mathieu C,et al.Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass[J].Diabetologia,2010,53(4):614-623.
[35]	Shao S,He F,Yang Y,et al.B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in type 1 diabetes[J].Cell Immunol,2012,280(1):16-21.
[36]	Grishman EK,White PC,Savani RC.Toll-like receptors,the NLRP3 inflammasome,and interleukin-1β in the development and progression of type 1 diabetes[J].Pediatr Res,2012(71):626-632.
[37]	Moran A,Bundy B,Becker DJ,et al.Interleukin-1 antagonism in type 1 diabetes of recent onset:two multicentre,randomised,double-blind,placebo-controlled trials[J].Lancet,2013,381(9 881):1 905-1 915.
[38]	Ablamunits V,Henegariu O,Hansen JB,et al.Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 Blockade evidence of improved immune regulation[J].Diabetes,2012,61(1):145-154.
[39]	Long SA,Buckner JH,Greenbaum CJ.IL-2 therapy in type 1 diabetes:“trials” and tribulations[J].Clin Immunol,2013,149(3):324-331.
[40]	Grinberg-Bleyer Y,Baeyens A,You S,et al.IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells[J].J Exp Med,2010,207(9):1 871-1 878.
[41]	Long SA.Rapamycin plus IL 2 combination therapy in subjects with T1D results in a sustained increase in IL 2 responsiveness and a transient decrease in C-peptide levels[C].Proceedings of the 71st Scientific Sessions American Diabetes Association Annual Meeting,2011:24-28.
[42]	Waldron-Lynch F,Kareclas P,Irons K,et al.Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes(DILT1D):a non-randomised,open label,adaptive dose finding trial[J].BMJ Open,2014,4(6):e005559.
[43]	Padgett LE,Broniowska KA,Hansen PA,et al.The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis[J].Ann N Y Acad Sci,2013,1 281(1):16-35.
[44]	Mastrandrea L,Yu J,Behrens T,et al.Etanercept treatment in children with new-onset type 1 diabetes pilot randomized,placebo-controlled,double-blind study[J].Diabetes Care,2009,32(7):1 244-1 249.
[45]	Faustman DL,Wang L,Okubo Y,et al.Proof-of-concept,randomized,controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes[J].PLoS One,2012,7(8):e41756.
[46]	Lind M,Jendle J,Torffvit O,et al.Glucagon-like peptide 1(GLP-1)analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction[J].Prim Care Diabetes,2012,6(1):41-46.
[47]	Kielgast U,Krarup T,Holst JJ,et al.Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function[J].Diabetes Care,2011,34(7):1 463-1 468.
[48]	Garg SK,Moser EG,Bode BW,et al.Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes:investigator-initiated,double-blind,randomized,placebo-controlled trial[J].Endocr Pract,2013,19(1):19-28.
[49]	Ellis SL,Moser EG,Snell-Bergeon JK,et al.Effect of sitagliptin on glucose control in adult patients with type 1 diabetes:a pilot,double-blind,randomized,crossover trial[J].Diabet Med,2011,28(10):1 176-1 181.
[50]	Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8⁺ effector memory T cells based on CD2 expression[J].Am J Transplant,2011,11(1):22-33.
[51]	Weinberg A,Boulware D,Dighero B,et al.Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes[J].Vaccine,2013,31(42):4 791-4 794.
[52]	Orban T,Bundy B,Becker DJ,et al.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes:a randomised,double-blind,placebo-controlled trial[J].Lancet,2011,378(9 789):412-419.
[53]	Park MH,Igarashi K.Polyamines and their metabolites as diagnostic markers of human diseases[J].Biomol Ther,2013,21(1):1-9.
[54]	Tersey SA,Colvin SC,Maier B,et al.Protective effects of polyamine depletion in mouse models of type 1 diabetes:implications for therapy[J].Amino acids,2014,46(3):633-642.
[55]	Wu J,Liu XR,Yang X,et al.Hypoglycemic effect of Lactococcus lactis vaccine containing HSP65-6P277 on streptozotocin-induced type 1 diabetic mice[J].J China Pharm Univ(中国药科大学学报),2014, 45(1):106-110.

Cited By

Get Citation

PDF

XML

Article views (1326) PDF downloads (1095)

Turn off MathJax

Article Contents

Abstract

References

Clinical development of type 1 diabetes vaccine

Abstract

References

Catalog

Export File

Citation

Format

Content